1
« Last post by Chip on December 31, 2025, 11:35:30 AM »
I found several including from Amazon, testclear.com and 4uhealth.com. I suggest using ChatGPT as I did and state your location. For more details of go to the links above and check them out. Here is the reply from my query to ChatGPT: Here are real options in the USA if you want to test urine at home for opiates (which includes hydromorphone metabolites):
ScreenClear 9‑Panel Urine Drug Test Kit Cup
ScreenClear 6‑Panel Urine Drug Test Kit
$15.10 • Oz Drug Tests
$7.15 • Oz Drug Tests
🔎 Quick overview
ScreenClear 9‑Panel Urine Drug Test Kit Cup – Multi-panel test in a cup format you can use at home. Typical panel includes opiates (OPI) which will react if hydromorphone metabolites are present above the cutoff.
ScreenClear 6‑Panel Urine Drug Test Kit – Cheaper/basic option. Detects standard drug panels including opiates (codeine/morphine/hydrocodone/hydromorphone in many opiate panels).
�
testclear.com
SoberGuard 6 Urine Drug Test Dip Card – Dip card style (not a cup) with multiple panels, including opiates. Good if you want separate test lines per substance.
Notes on hydromorphone detection
Standard “opiates” immunoassay panels on over-the-counter kits do include hydromorphone metabolites in their cross-reactive group at typical cutoffs, so they’ll likely show positive if there’s enough in urine. �
testclear.com
These kits don’t measure concentration — only “present/absent” above a cutoff.
They’re for personal/peace-of-mind use, not legal, employment, or clinical diagnostics. For confirmed quantitative results, a lab test (like LC-MS/MS) would be needed. �
4U Health Inc.
Where you can buy
You can order these kits online from major retailers (Amazon, Oz Drug Tests, drug testing supply stores) and have them shipped to the USA. Most ship either directly or through third-party sellers — just check the listing for delivery details.
If you need something that’s specifically designed to detect hydromorphone (not just the opiates panel), the only options are lab-based confirmatory tests (ordered through a clinic or lab service), not typical over-the-counter strips.
�
mml.testcatalog.org
2
Does anyone know where I can get an at home urine test for Hydromorphone?
3
« Last post by Chip on December 21, 2025, 04:22:43 PM »
Modification Update Version Checker v1.1 https://custom.simplemachines.org/index.php?mod=4335Automaticlly checks if there are new versions of modifications that you have installed. Adds a system to auto check for updates for modifications that are installed from simplemachines.org mod site. Display latest updates for mods in the admin dashboard, and browse packages page. Updates can be run manually via the Check for Modifications Update button in the browse packages area or automatically via the scheduled task that runs once a day by default.
4
« Last post by smfadmin on December 21, 2025, 03:36:17 PM »
⚖️ Comprehensive Harm‑Reduction Overview: Stopping Clopixol Depot (Zuclopenthixol Decanoate) PurposeThis post compiles general patterns reported by individuals who discontinue a long‑acting antipsychotic depot. It is descriptive, not prescriptive. Experiences vary widely depending on dose, duration, metabolism, stress load, and individual neurochemistry. ✅ Potential Benefits of Discontinuation1. Reduced Sedation & Cognitive Drag- Less daytime fatigue
- Sharper cognition and faster processing
- Improved reaction time
- Better initiative and drive
2. Reduction in Extrapyramidal Symptoms (EPS)- Less rigidity or stiffness
- Reduced tremor
- Less akathisia
- Improved motor fluidity
3. Emotional “Unflattening”- More emotional range
- Less blunting
- Improved libido
- Better reward sensitivity and motivation
4. Increased Autonomy & Self‑Management- No depot appointments
- More control over neurochemistry
- Ability to fine‑tune personal regimen based on lived experience
5. Reduced Pharmacological Load- Lower anticholinergic burden
- Reduced metabolic drag
- Less prolactin elevation
- Lower cardiovascular strain
⚠️ Risks of Discontinuation1. Return of Underlying Symptoms- Psychosis
- Paranoia
- Agitation
- Sleep disruption
- Disorganized or intrusive thinking
Note: Depot fade is slow. Relapse can occur 2–8 weeks after the last injection.2. Rebound / Withdrawal‑Like Effects- Anxiety
- Restlessness
- Insomnia
- Irritability
- Transient dysphoria
3. Withdrawal Dyskinesia (Uncommon)- Involuntary movements
- Facial/tongue movements
- Typically temporary
4. Loss of Protective Buffer- Reduced mood stabilization
- Loss of anti‑agitation effect
- No antipsychotic coverage during stressors
5. Increased Sensitivity to Other Substances- Stimulants may feel stronger
- GABAergic rebound may be more pronounced
- THC can become destabilizing
🧠 Neutral / Individual‑Dependent Factors- Sleep quality
- Appetite
- Stress tolerance
- Emotional intensity
- Impulse control
🗓️ Timeline: Commonly Reported Patterns After Stopping a DepotWeek 0–1: Immediate Post‑Depot Period- Depot still active; plasma levels decline slowly.
- Most people feel no major change yet.
- Sedation, EPS, and emotional blunting remain largely unchanged.
- Some report subtle increases in alertness or energy.
Week 2–3: Early Fade Phase- Sedation may begin to lighten.
- Cognitive clarity may improve slightly.
- EPS (if present) may start to ease.
- Some individuals report mild restlessness or sleep changes.
- Underlying symptoms typically remain stable due to residual depot effect.
Week 4–5: Mid‑Fade Window- Noticeable reduction in sedation for many.
- Emotional range may increase (“unflattening”).
- Motor side‑effects often continue improving.
- Some may experience transient anxiety, irritability, or sleep disruption as dopamine blockade decreases.
- This is often the earliest point where underlying symptoms may begin to re‑emerge in sensitive individuals.
Week 6–8: Late Fade / Vulnerability Window- Depot effect significantly reduced.
- Cognitive sharpness and motivation may increase further.
- Emotional intensity may feel stronger — positive or negative.
- Some individuals report rebound‑type effects (restlessness, insomnia, agitation).
- This is the period where relapse risk is typically highest if underlying symptoms were previously controlled by the depot.
- Rarely, withdrawal dyskinesia may appear as dopamine receptors re‑sensitize.
Week 9–12: Post‑Depot Baseline Emerges- Most or all pharmacological effect has worn off.
- Side‑effects (sedation, EPS, blunting) are usually minimal or gone.
- Neurochemistry stabilizes into a new baseline.
- Underlying symptoms — if they return — often do so in this window.
- Sensitivity to stimulants, THC, and GABAergic agents may be higher than before.
3 Months and Beyond- Long‑term baseline becomes clearer.
- Some individuals feel significantly better without the depot.
- Others may experience recurring symptoms depending on stress load and personal history.
- Motor and cognitive improvements (if any) tend to plateau.
📌 Summary (SMF‑Compatible Header Simulation)Cognition- Benefit: Sharper, less sedated
- Risk: Possible agitation or insomnia
Motor System- Benefit: Less EPS
- Risk: Withdrawal dyskinesia (rare)
Emotion- Benefit: More range, less blunting
- Risk: Mood instability
Psychosis Risk- Benefit: —
- Risk: Relapse risk increases
Autonomy- Benefit: Full control
- Risk: Loss of safety buffer
Pharmacology- Benefit: Reduced anticholinergic load
- Risk: Dopamine rebound effects
Notes- Depot pharmacokinetics vary; some people metabolize faster or slower.
- Stress, sleep, substance use, and environment strongly influence outcomes.
- This post is descriptive, not advisory.
5
« Last post by smfadmin on December 19, 2025, 10:39:35 AM »
RELATIONSHIPS:
1. No man wants a woman who is accessible to every man.
2. You will reach the age where you can easily tell that the relationship is not going to work just by the conversation.
3. If you have to beg someone to do the bare minimum for you and if you have to keep telling them how you deserved to be treated better then for goodness sake. LEAVE. It's not worth your peace.
4. Don’t ignore the red flags you see at the beginning. The red flags you ignore trying to see the good in people WILL cost you later.
5. Just because a person keeps you around doesn’t mean they love you; remember, people, buy cats just to get rid of rats.
6. If SEX is all you are about in a relationship, then it means you are actually empty. A healthy relationship is about purpose! Sharing visions and values together.
7. In life, you need to learn to stop opening doors for toxic people and giving them room in your mind, and calling it "seeking closure!" You're delaying your healing process.
8. Avoid the damaged, the unhappy, and the unlucky.
9. Anger opens the mouth and shuts the mind. Control your. Anger so that you can think fast and get solution to what cause your anger
10. As a woman, understand that men will say and do anything to sleep with you. Look at the actions, don’t be blinded by words. Anyone can talk a good game, but it takes a real ball player to play.
6
« Last post by Chip on December 19, 2025, 04:39:21 AM »
[title]Urine Drug Testing – Cocaine & Methamphetamine (MA)[/title]
Scope
This page covers typical urine detection windows for cocaine and methamphetamine (MA), including chronic-use scenarios. Times assume standard lab immunoassay cut-offs.
Cocaine
What is detected:
• Benzoylecgonine (main metabolite)
• Cocaine itself clears very fast
Detection window (urine):
• Single / occasional use: 2–3 days
• Heavy or repeated use: 5–7 days
• Extreme binges (rare): up to 10–14 days
Notes:
• Cocaine has one primary metabolite
• Short-lived compared to stimulants like MA
• Most users are clear within 72 hours
Methamphetamine (MA)
What is detected:
• Methamphetamine
• Amphetamine (active metabolite – this is the limiter)
Detection window (urine):
• Single / light use: 2–4 days
• One-day heavy use: 4–6 days
• Multi-day binge (2–4 days): 6–8 days
• Chronic / high-dose use: 8–10 days
• Outliers (daily, long-term use): up to 14 days
Why MA lasts longer than cocaine:
• Converts to amphetamine
• Amphetamine accumulates with repeated use
• Chronic use causes metabolite stacking
Route of Use
• IV / smoked: slightly longer tail
• Nasal: middle
• Oral: slightly shorter
Frequency and total dose matter far more than route
Urine pH & Hydration
• Alkaline urine = slower excretion
• Acidic urine = faster excretion
• Labs account for dilution; hydration does not “cheat” tests
Rule of Thumb
• Cocaine: usually clear in ≤3 days
• MA single use: ~3–4 days
• MA binge: ~7 days
• MA chronic: 10+ days possible
Important:
Long detection times are driven by chronic daily use without breaks, not isolated doses.
7
« Last post by Chip on December 09, 2025, 10:16:21 AM »
https://www.wired.com/story/a-fentanyl-vaccine-is-about-to-get-its-first-major-test/?utm_source=nl&utm_brand=wired&utm_mailing=WIR_Science_120825&utm_campaign=aud-dev&utm_medium=email&utm_term=WIR_Science&utm_content=WIR_Science_120825&bxid=67883001cdeb6340250c3d97&cndid=85787720&hasha=c9edd795ab58c731e64cc2832451a46d&hashb=92cd5a4e4f9a554757364e6cc6a52d8ff33f14ec&hashc=1e7f7a9239bb44f191dc979b8fe5e634e587dfe020b84a653d2040468a8b342b&esrc=bx_multi1st_science* There is an audio file available at the link A Fentanyl Vaccine Is About to Get Its First Major TestDec 3, 2025 ARMR Sciences of New York is trialing a vaccine in the Netherlands to protect against fentanyl-related overdose and death. Just a tiny amount of fentanyl, the equivalent of a few grains of sand, is enough to stop a person’s breathing. The synthetic opioid is tasteless, odorless, and invisible when mixed with other substances, and drug users are often unaware of its presence. PHOTO-ILLUSTRATION: WIRED STAFF; GETTY IMAGES:
8
« Last post by Chip on December 07, 2025, 09:27:29 AM »
https://neurosciencenews.com/episodic-memory-change-30022/Why Memories Change: How the Brain Rewrites the PastDecember 5, 2025 Summary: A new review explores how episodic memories are formed, stored, and reshaped over time, revealing why our recollections of past events often change. Rather than functioning like fixed files, memories consist of multiple components that can lie dormant until triggered by environmental cues. When retrieved, these components blend with general knowledge, past experiences, and current context, creating updated versions of the original event. The findings help explain memory distortion and offer insights for mental health, learning, and legal settings where accuracy matters. Neuroscience News logo for mobile. This shows a head and a brain. A key part of the study focused on how the brain physically stores memories, highlighting the role of the hippocampus - a part of the brain that helps form and organise memories. Credit: Neuroscience News Why Memories Change: How the Brain Rewrites the Past FeaturedNeuroscience·December 5, 2025 Summary: A new review explores how episodic memories are formed, stored, and reshaped over time, revealing why our recollections of past events often change. Rather than functioning like fixed files, memories consist of multiple components that can lie dormant until triggered by environmental cues. When retrieved, these components blend with general knowledge, past experiences, and current context, creating updated versions of the original event. The findings help explain memory distortion and offer insights for mental health, learning, and legal settings where accuracy matters. Key Facts * Dynamic Memories: Episodic memories are continually updated, not stored as perfect copies. * Trigger-Based Recall: Hidden memory traces become conscious only when activated by cues. * Real-World Impact: Memory reshaping affects mental health, education, and legal decision-making. Source: University of East Anglia A study from the University of East Anglia is helping scientists better understand how our brains remember past events – and how those memories can change over time. A new paper published today explores episodic memory – the kind of memory we use to recall personal experiences like a birthday party or a holiday. The team say their work has important implications for mental health, education, and legal settings where memory plays a key role. The article continues at the source link above ...
9
« Last post by smfadmin on December 04, 2025, 01:53:58 PM »
1,4-Butanediol (1,4-BDO) / GHB Overview and Urine-Analysis
Key Points:- 1,4-BDO is metabolized in the body into GHB.
- Urine tests usually detect GHB, not 1,4-BDO itself.
- Detection times are short due to rapid metabolism.
Detection Windows| [th]Sample Type[/th][th]Detection Window[/th][th]Notes[/th] | | Urine (standard test) | ~6–12 hours | Most standard tests detect GHB shortly after use. | | Urine (sensitive forensic tests) | Up to 24 hours | Highly sensitive labs may detect metabolites longer. | | Blood / Plasma | ~1–4 hours | Very short; rapid metabolism to GHB. | | Hair | Up to 90 days | Can detect repeated or chronic use; single use detection less reliable. |
Urine Clearance Timeline (Approximate)Time after ingestion → Likely Detection in Urine
0–2 hrs █████████████ Very high (recent use)
2–6 hrs ████████ High
6–12 hrs ████ Moderate → Low
12–24 hrs ██ Low → Rare
>24 hrs ░ Usually undetectable
Effects of 1,4-BDO (Conceptual, Tolerance Considered)| [th]1,4-BDO Dose (mL)[/th][th]GHB Equivalent (g)[/th][th]Naïve User Effects[/th][th]High-Tolerance User Effects[/th][th]Risk Level[/th] | | 1–2 | 0.6–1.2 | Mild euphoria, relaxation, light sedation | Mild relaxation, slight euphoria | Low | | 3–4 | 1.8–2.4 | Strong euphoria, impaired coordination, nausea | Euphoria, relaxation, moderate sedation | Moderate | | 5–6 | 3–3.6 | Heavy sedation, risk of vomiting, blackouts | Strong euphoria, sedation, impaired motor skills | High | | 6.8 | ~4.1 | Very strong sedation, high risk of unconsciousness, vomiting, respiratory depression | Strong sedation, euphoria, risk of blackouts, still significant overdose potential | Very High | | 7–8 | 4.2–4.8 | Life-threatening overdose | Severe sedation, risk of unconsciousness, respiratory depression | Critical |
Conceptual Risk Pattern (Traffic-Light System)🟢 LOW | Light psychoactive effects possible. Function mostly intact.
🟡 MODERATE | Clear intoxication. Impaired coordination, sedation. Judgment reduced. Higher chance of vomiting or blackouts.
🟠 HIGH | Heavy sedation. Major impairment, possible amnesia. Sleep-like states, difficult to wake. Danger increases massively with any combo (alcohol, benzos, opioids).
🔴 VERY HIGH | High risk of overdose. Loss of consciousness, irregular breathing. Vomiting while unconscious possible. Risk of respiratory depression.
⚫ CRITICAL | Severe overdose range. Slow or stopped breathing. Medical emergency—risk of coma or death.
Important Safety Notes- Even high-tolerance users remain at serious risk at higher doses.
- Effects onset: ~15–30 min, peak ~45–90 min, duration 2–4 h.
- Mixing with alcohol or other depressants greatly increases risk.
- Tolerance does not prevent respiratory depression or overdose.
Disclaimer: This post is for informational purposes only and does not provide instructions for use. 1,4-BDO/GHB use carries significant risk of serious injury or death.
10
« Last post by smfadmin on December 04, 2025, 01:29:57 AM »
https://www.psychiatrist.com/jcp/brexpiprazole-co-occurring-schizophrenia-substance-use-disorder-randomized-controlled-trial/?utm_source=Klaviyo&utm_medium=email&utm_campaign=news_wmr&klid=01HYSTTNXNB74YAYKT9XMYQCN0&_kx=va3uRF3O8-7Dg_zjrKMZJk0wdery-TOTVyZ3l8muM1g.VpkqxCBrexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder: A Multisite, Randomized, Controlled TrialOctober 13, 2025 Abstract Objective: This proof-of-concept study examined the effects of brexpiprazole treatment on substance use, psychiatric symptoms, and quality of life in patients with co-occurring schizophrenia and substance use disorder. Methods: In this 12-week study, patients diagnosed with schizophrenia and substance use disorder using DSM-5 criteria were randomly assigned to switch from their current antipsychotic medication to brexpiprazole (up to 4 mg/day) or remain on their current antipsychotic treatment (treatment as usual [TAU]). Substance use was assessed by the number of days of substance use and the dollars spent on substance in the past week, and substance craving was assessed using the Visual Analog Scale (VAS). Quality of life was assessed using the Heinrichs-Carpenter Quality of Life Scale (QOL). In addition, psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression Scale-Severity of Illness. Results: Thirty-nine patients were randomized (21 in the brexpiprazole group, 18 in the TAU group). Mixed models for repeated measures showed that, despite the lack of statistical significance, a consistent pattern of decrease in the brexpiprazole group was observed for the number of days of substance use and the dollars spent, as well as substance craving; the brexpiprazole group had a 15.5 points greater decrease in VAS (P=.157) and a $33.3 greater decrease in the dollars spent (P=.108) from baseline to week 12 compared with the TAU group. The brexpiprazole group did show a statistically significant 8.9 points greater increase in QOL compared with the TAU group (P =.020). Even though it was not statistically significant, the brexpiprazole group had a 2.4-point greater decrease in the PANSS General Psychopathology subscale score (P=.150) and a 1.9-point greater decrease in the PANSS Negative Symptom subscale score (P=.126) compared with the TAU group. Conclusion: This study suggests that brexpiprazole might be beneficial in reducing substance craving and use in patients with schizophrenia and co-occurring substance use disorder; this potential benefit may help improve quality of life and overall psychiatric symptoms in a difficult-to-treat patient population.
|
Recent Posts
